Advertisement

Annals of Hematology

, Volume 98, Issue 11, pp 2485–2496 | Cite as

Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis

  • Xia Wu
  • Huifang Wang
  • Jili Deng
  • Xue Zheng
  • Yantao Ling
  • Yuping GongEmail author
Review Article

Abstract

Ecotropic virus integration site-1 (EVI1) is frequently expressed in patients with acute myeloid leukemia (AML). Many studies have reported the potential poor prognostic impact of EVI1 higher expression (EVI1H) in the AML patients; however, the conclusions previously reported have not been fully assessed and are still controversial. Therefore, we performed a meta-analysis to evaluate the prognostic significance of EVI1H in patients with AML. The primary endpoint was overall survival (OS), and the event-free survival (EFS) was selected as the secondary endpoint. We extracted the hazard ratio (HR) and their 95% confidence interval (CI) for the OS and EFS from the multivariate COX proportional hazard models. A total of 4767 AML patients from 11 studies up to 23 February 2019 were subjected to our meta-analysis. Pooled HRs suggested that EVI1H had an adverse impact on OS (HR = 1.52, 95%CI 1.24–1.86) and EFS (HR = 1.41, 95%CI 1.14–1.74) in AML patients. EVI1H was also associated with a shorter OS (HR = 1.73, 95%CI 1.43–2.11) and EFS (HR = 1.17, 95%CI 1.05–1.31) in AML patients with the intermediate cytogenetic risk (ICR) according to the National Comprehensive Cancer Network (NCCN), European leukemia network (ELN), or International System for Human Cytogenetic Nomenclature (ISCN). Furthermore, EVI1H appeared to be a poor prognosis indicator in patients with normal cytogenetics (NC) (HR for OS:2.01, 95%CI 1.32–3.05; HR for EFS 1.54, 95%CI 1.09–2.17) and young patients (HR for OS 1.30, 95%CI 1.09–1.55), respectively. This meta-analysis indicates EVI1H has an independent and significantly adverse prognostic impact on AML patients in the entire population, and this conclusion same applies to some subgroups like AML patients with ICR, NC, and young AML patients.

Keywords

EVI1 Expression Acute myeloid leukemia Prognosis Meta-analysis 

Notes

Author contributions

Conceptualization: Xia Wu, Yuping Gong.

Studies screen: Xia Wu, Jili Deng, Huifang Wang.

Collection Of data: Xia Wu, Jili Deng, Huifang Wang.

Analysis of data: Xia Wu, Yantao Ling, Xue Zheng.

Funding acquisition: Yuping Gong.

Methodology: Xia Wu, Xue Zheng, Yantao Ling.

Writing-original draft: Xia Wu, Yuping Gong.

Writing-review & editing: Xia Wu, Yuping Gong.

Funding

The work was supported by the Foundation of the Science & Technology Department of Sichuan Province (NO. 2015SZ0234-5) and Foundation of Chengdu Science and Technology Bureau (NO. 2016-HM01-00001-SF).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

277_2019_3774_MOESM1_ESM.docx (1.5 mb)
ESM 1 (DOCX 1.51 mb)
277_2019_3774_MOESM2_ESM.pdf (89 kb)
ESM 2 (PDF 89.3 kb)

References

  1. 1.
    Short NJ, Rytting ME, Cortes JE (2018) Acute myeloid leukaemia. Lancet (London, England) 392(10147):593–606.  https://doi.org/10.1016/s0140-6736(18)31041-9 CrossRefGoogle Scholar
  2. 2.
    Theilgaard-Monch K, Boultwood J, Ferrari S, Giannopoulos K, Hernandez-Rivas JM, Kohlmann A, Morgan M, Porse B, Tagliafico E, Zwaan CM, Wainscoat J, Van den Heuvel-Eibrink MM, Mills K, Bullinger L (2011) Gene expression profiling in MDS and AML: potential and future avenues. Leukemia 25(6):909–920.  https://doi.org/10.1038/leu.2011.48 CrossRefPubMedGoogle Scholar
  3. 3.
    Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447.  https://doi.org/10.1182/blood-2016-08-733196 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Marcucci G, Haferlach T, Dohner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol : Off J Am Soc Clin Oncol 29(5):475–486.  https://doi.org/10.1200/jco.2010.30.2554 CrossRefGoogle Scholar
  5. 5.
    Kataoka K, Kurokawa M (2012) Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis. Cancer Sci 103(8):1371–1377.  https://doi.org/10.1111/j.1349-7006.2012.02303.x CrossRefPubMedGoogle Scholar
  6. 6.
    Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse HC 3rd, Jenkins NA, Copeland NG (1988) Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 8(1):301–308.  https://doi.org/10.1128/mcb.8.1.301 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN (1988) Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54(6):831–840CrossRefGoogle Scholar
  8. 8.
    Goyama S, Kurokawa M (2009) Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci 100(6):990–995.  https://doi.org/10.1111/j.1349-7006.2009.01152.x CrossRefPubMedGoogle Scholar
  9. 9.
    Hinai AA, Valk PJ (2016) Review: aberrant EVI1 expression in acute myeloid leukaemia. Br J Haematol 172(6):870–878.  https://doi.org/10.1111/bjh.13898 CrossRefPubMedGoogle Scholar
  10. 10.
    Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Lowenberg B, Delwel R (2008) High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111(8):4329–4337.  https://doi.org/10.1182/blood-2007-10-119230 CrossRefPubMedGoogle Scholar
  11. 11.
    Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Lowenberg B, Delwel R (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101(3):837–845.  https://doi.org/10.1182/blood-2002-05-1459 CrossRefPubMedGoogle Scholar
  12. 12.
    Groschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kuhn MW, Eiwen K, Erpelinck C, Havermans M, Lubbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Lowenberg B, Dohner K, Dohner H, Delwel R (2013) Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian acute myeloid leukemia study group and the Dutch-Belgian-Swiss HOVON/SAKK cooperative group. J Clin Oncol : Off J Am Soc Clin Oncol 31(1):95–103.  https://doi.org/10.1200/jco.2011.41.5505 CrossRefGoogle Scholar
  13. 13.
    Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, van Putten WL, Lowenberg B, Valk PJ (2011) Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 118(4):1069–1076.  https://doi.org/10.1182/blood-2011-02-334748 CrossRefPubMedGoogle Scholar
  14. 14.
    Groschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lubbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Dohner H, Lowenberg B, Dohner K, Delwel R (2010) High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol: Off J Am Soc Clin Oncol 28(12):2101–2107.  https://doi.org/10.1200/jco.2009.26.0646 CrossRefGoogle Scholar
  15. 15.
    Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R (2008) Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes, Chromosomes & Cancer 47(4):288–298.  https://doi.org/10.1002/gcc.20532 CrossRefGoogle Scholar
  16. 16.
    Vazquez I, Maicas M, Cervera J, Agirre X, Marin-Bejar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, Valencia A, Brunet S, Lumbreras E, Prosper F, Gomez-Casares MT, Hernandez-Rivas JM, Calasanz MJ, Sanz MA, Sierra J, Odero MD (2011) Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica 96(10):1448–1456.  https://doi.org/10.3324/haematol.2011.040535 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Qin YZ, Zhao T, Zhu HH, Wang J, Jia JS, Lai YY, Zhao XS, Shi HX, Liu YR, Jiang H, Huang XJ, Jiang Q (2018) High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy. Med Sci Monit : Int Med J Exp Clin Res 24:758–767CrossRefGoogle Scholar
  18. 18.
    Yamato G, Yamaguchi H, Handa H, Shiba N, Kawamura M, Wakita S, Inokuchi K, Hara Y, Ohki K, Okubo J, Park MJ, Sotomatsu M, Arakawa H, Hayashi Y (2017) Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia. Genes, Chromosomes Cancer 56(11):800–809.  https://doi.org/10.1002/gcc.22483 CrossRefPubMedGoogle Scholar
  19. 19.
    Langabeer SE, Rogers JR, Harrison G, Wheatley K, Walker H, Bain BJ, Burnett AK, Goldstone AH, Linch DC, Grimwade D (2001) EVI1 expression in acute myeloid leukaemia. Br J Haematol 112(1):208–211CrossRefGoogle Scholar
  20. 20.
    Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de Graaf SS, Reinhardt D, Creutzig U, Kaspers GJ, de Bont ES, Stary J, Trka J, Zimmermann M, Beverloo HB, Pieters R, Delwel R, Zwaan CM, van den Heuvel-Eibrink MM (2010) EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia 24 (5):942–949. doi: https://doi.org/10.1038/leu.2010.47 CrossRefGoogle Scholar
  21. 21.
    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http:// www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  22. 22.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 327(7414):557–560.  https://doi.org/10.1136/bmj.327.7414.557 CrossRefGoogle Scholar
  23. 23.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefGoogle Scholar
  24. 24.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res) 315(7109):629–634.  https://doi.org/10.1136/bmj.315.7109.629 CrossRefGoogle Scholar
  25. 25.
    Zhu YM, Wang PP, Huang JY, Chen YS, Chen B, Dai YJ, Yan H, Hu Y, Cheng WY, Ma TT, Chen SJ, Shen Y (2017) Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance. J Transl Med 15(1):178.  https://doi.org/10.1186/s12967-017-1279-4 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Bou Samra E, Klein B, Commes T, Moreaux J (2012) Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. Oncotarget 3(8):824–832.  https://doi.org/10.18632/oncotarget.571 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, Chiba S, Kurokawa M (2008) Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3(2):207–220.  https://doi.org/10.1016/j.stem.2008.06.002 CrossRefPubMedGoogle Scholar
  28. 28.
    Wieser R (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396(2):346–357.  https://doi.org/10.1016/j.gene.2007.04.012 CrossRefPubMedGoogle Scholar
  29. 29.
    Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, Kurokawa M (2011) Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117(13):3617–3628.  https://doi.org/10.1182/blood-2009-12-261602 CrossRefPubMedGoogle Scholar
  30. 30.
    Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y, Kurokawa M (2009) Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene 28(49):4364–4374.  https://doi.org/10.1038/onc.2009.288 CrossRefPubMedGoogle Scholar
  31. 31.
    Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, Suda T, Morishita K (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 24(11):1976–1987.  https://doi.org/10.1038/sj.emboj.7600679 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Glass C, Wuertzer C, Cui X, Bi Y, Davuluri R, Xiao YY, Wilson M, Owens K, Zhang Y, Perkins A (2013) Global identification of EVI1 target genes in acute myeloid leukemia. PLoS One 8(6):e67134.  https://doi.org/10.1371/journal.pone.0067134 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of HematologyWest China Hospital, Sichuan UniversityChengduChina

Personalised recommendations